Molecular upgrading of grade 2 astrocytomas in the era of targeted IDH inhibition: Are we ready for the therapeutic consequences?
- 4 September 2026
- journal article
- Published by Oxford University Press (OUP) in Neuro-Oncology
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- cIMPACT-NOW update 12: Refining Pathology-based Risk Stratification and Grading for IDH-mutant GliomasNeuro-Oncology, 2026
- Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trialThe Lancet Oncology, 2025
- Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaNew England Journal of Medicine, 2023
- Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH -wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON TrialClinical Cancer Research, 2022
- Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I TrialClinical Cancer Research, 2021